Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDLineage Cell Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.07 | -$0.02 | -$0.04 |
| Q2 2024 | 1 | -$0.09 | -$0.03 | -$0.05 |
| Q3 2024 | 1 | -$0.08 | -$0.02 | -$0.04 |
| Q4 2024 | 3 | -$0.21 | $0.06 | -$0.03 |
| Q1 2025 | 1 | -$0.08 | -$0.02 | -$0.04 |
| Q2 2025 | 1 | -$0.08 | -$0.02 | -$0.04 |
| Q3 2025 | 1 | -$0.07 | -$0.02 | -$0.04 |
| Q4 2025 | 1 | -$0.01 | -$0.00 | -$0.01 |
| Q1 2026 | 1 | -$0.10 | -$0.03 | -$0.05 |
| Q2 2026 | 1 | -$0.10 | -$0.03 | -$0.05 |
| Q3 2026 | 1 | -$0.10 | -$0.03 | -$0.05 |
| Q4 2026 | 1 | -$0.10 | -$0.03 | -$0.05 |
Lineage Cell Therapeutics, Inc. Earnings Date And Information
Lineage Cell Therapeutics, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-0.02 earnings per share for the quarter, missing analysts' consensus estimates of $-0.01303 by $0.00697. The company had revenue of 3.78 M for the quarter and had revenue of 8.95 M for the year. Lineage Cell Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.12 diluted earnings per share) and currently has a price-to-earnings ratio of -5.24. Lineage Cell Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based on prior year's report dates.
Lineage Cell Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.01 | -$0.02 | -0 | $1.03 M | $3.78 M |
| 08/08/2024 | Q2 2024 | -$0.02 | -$0.03 | -0.01 | $943,200 | $1.41 M |
| 05/09/2024 | Q1 2024 | -$0.04 | -$0.04 | 0 | $1.44 M | |
| 03/07/2024 | Q4 2023 | -$0.07 | -$0.03 | 0.04 | $2.09 M | |
| 11/09/2023 | Q3 2023 | -$0.04 | -$0.04 | -0 | $2.60 M | $1.25 M |
| 08/10/2023 | Q2 2023 | -$0.02 | -$0.03 | -0.01 | $2.20 M | $3.23 M |
| 05/11/2023 | Q1 2023 | -$0.02 | -$0.03 | -0 | $2.39 M | |
| 03/09/2023 | Q4 2022 | -$0.03 | -$0.04 | -0.01 | $1.92 M | |
| 11/10/2022 | Q3 2022 | -$0.04 | -$0.04 | -0 | $3.90 M | $3.00 M |
| 08/11/2022 | Q2 2022 | -$0.04 | -$0.06 | -0.02 | $3.68 M | $4.55 M |
| 05/12/2022 | Q1 2022 | -$0.03 | -$0.05 | -0.01 | $5.24 M | |
| 03/10/2022 | Q4 2021 | -$0.01 | -$0.17 | -0.16 | $960,000 | |
| 11/10/2021 | Q3 2021 | -$0.05 | -$0.05 | 0 | $510,000 | $2.20 M |
| 08/12/2021 | Q2 2021 | -$0.03 | -$0.03 | -0 | $725,000 | $441,000 |
| 05/13/2021 | Q1 2021 | -$0.04 | -$0.01 | 0.03 | $293,000 | |
| 03/11/2021 | Q4 2020 | -$0.05 | $0.01 | 0.06 | $166,000 | |
| 11/04/2020 | Q3 2020 | -$0.05 | -$0.05 | -0 | $563,333 | $342,000 |
| 08/06/2020 | Q2 2020 | -$0.04 | -$0.04 | -0 | $557,750 | $99,000 |
| 05/07/2020 | Q1 2020 | -$0.05 | -$0.06 | -0.01 | $166,000 | |
| 03/12/2020 | Q4 2019 | -$0.07 | -$0.03 | 0.04 | $832,000 |
Lineage Cell Therapeutics, Inc. Earnings: FAQ's
When is Lineage Cell Therapeutics, Inc.'s earnings date?
Lineage Cell Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based off last year's report dates.
How can I listen to Lineage Cell Therapeutics, Inc.'s earnings conference
call?
The conference call for Lineage Cell Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Lineage Cell Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Lineage Cell Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Lineage Cell Therapeutics, Inc. generate each year?
Lineage Cell Therapeutics, Inc. (:LCTX) has a recorded annual revenue of $8.95 M.
How much profit does Lineage Cell Therapeutics, Inc. generate each year?
Lineage Cell Therapeutics, Inc. (:LCTX) has a recorded net income of $8.95 M. Lineage Cell Therapeutics, Inc. has generated $-0.12 earnings per share over the last four quarters.
What is Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio?
Lineage Cell Therapeutics, Inc. (:LCTX) has a price-to-earnings ratio of -5.24 and price/earnings-to-growth ratio is -0.34.